Key result
Rotavirus vaccination may reduce celiac risk and delay type 1 diabetes, though evidence remains conflicting.
Why the study?
Whether rotavirus vaccination is associated with a reduced risk of developing celiac disease and other autoimmune diseases remains an unanswered question.
Does the rotavirus vaccine reduce the risk of developing celiac disease and other autoimmune diseases in children?
Does the rotavirus vaccine reduce the risk of developing celiac disease and other autoimmune diseases in children?
This review highlights a potential protective effect of the rotavirus vaccine against the development of celiac disease and other autoimmune conditions, warranting further research.
This review examines the risk of developing celiac disease (CD) and other autoimmune diseases in individuals receiving the rotavirus (RV) vaccine compared to the normal population. Celiac disease is a malabsorptive, chronic, immune-mediated enteropathy involving the small intestine. The pathogenesis of CD is multifactorial, and mucosal immunity plays an important role in its development. Low mucosal IgA levels significantly increase the risk of developing the disease. Rotavirus is an infectious agent that causes diarrhea, particularly in children aged 0-24 months, and is frequently involved in diarrhea-related deaths in these children. An oral vaccine against RV has been developed. While it is effective on RV infection, it also contributes to increasing mucosal immunity. Studies have indicated that individuals immunized with the RV vaccine are at lower risk of developing CD than unvaccinated individuals. In addition, the mean age for developing CD autoimmunity may be higher in the vaccinated group than in controls receiving placebo. Additional studies that include children immunized with different RV vaccines and unvaccinated children would provide more meaningful results. Although current data suggest a possible association of RV vaccination with a reduced risk of developing CD and other autoimmune diseases, this remains an unanswered question that merits greater international investigation.
No takes yet. Share an insight, caveat, or question.
İbrahim Kılıççalan (2021) conducted a review in Celiac disease and Type 1 Diabetes Mellitus. Rotavirus vaccine vs. Unvaccinated or placebo was evaluated. Rotavirus vaccination may reduce the risk of developing celiac disease and delay the onset of type 1 diabetes mellitus, though evidence across different populations and vaccine types remains conflicting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: